<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426956</url>
  </required_header>
  <id_info>
    <org_study_id>CM-CANA-18</org_study_id>
    <nct_id>NCT03426956</nct_id>
  </id_info>
  <brief_title>Glucose Absorption and Gut Hormone Secretion After Gastric Bypass</brief_title>
  <official_title>Impact of Canaglifloxin on Gut Hormone Secretion After Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the impact of canagliflozin on secretion of gut hormones, in particular
      glucagon-like peptide 1 (GLP-1) in gastric bypass operated patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glucose is a potent stimulus for GLP-1 secretion after gastric bypass surgery and the SGLT-1
      transporter appears to be crucial for this response. The study will investigate the effects
      of SGLT-1/SGLT-2 inhibition (by canagliflozin) on secretion of GLP-1 and other gut hormones
      after gastric bypass surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 8, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>10 gastric bypass patients</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in GLP-1 secretion (evaluated by iAUC).</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
    <description>Comparison of the GLP-1 responses (evaluated by iAUC) between the two test days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in glucose responses between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in insulin responses between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in C-peptide responses between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Gastric Inhibitory Peptide (GIP) responses (evaluated by iAUC) between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in peptide YY (PYY) responses (evaluated by iAUC) between the two test days.</measure>
    <time_frame>0-240 min following carbohydrate ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in glucagon responses (evaluated by iAUC) between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in oxyntomodulin responses (evaluated by iAUC) between the two test days.</measure>
    <time_frame>0-240 min following carbohydrate ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in cholecystokinin (CCK) responses (evaluated by iAUC) between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in bile acid responses (evaluated by iAUC) between the two test days.</measure>
    <time_frame>0-240 min following glucose ingestion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose + Canagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Ingestion of glucose (50 g) dissolved in 200 ml water.</description>
    <arm_group_label>Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose + Canagliflozin</intervention_name>
    <description>Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.</description>
    <arm_group_label>Glucose + Canagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢Uncomplicated gastric bypass surgery performed minimum 12 months prior to study

        Exclusion Criteria:

          -  Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery

          -  Pregnancy or breastfeeding

          -  Haemoglobin levels below 6,5 mM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sten Madsbad, Professor</last_name>
    <phone>+4538623032</phone>
    <email>sten.madsbad@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Endocrinology</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoffer Martinussen, MD</last_name>
      <phone>+4538623032</phone>
      <email>christoffer.martinussen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Christoffer Martinussen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Christoffer Martinussen</investigator_full_name>
    <investigator_title>Principal investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Glucagon-like Peptide-1</keyword>
  <keyword>Glucose</keyword>
  <keyword>Gastric bypass</keyword>
  <keyword>Bariatric surgery</keyword>
  <keyword>Obesity</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

